From our Annual Public Meeting to topic-specific convenings, the Reagan-Udall Foundation for the FDA brings stakeholders together on matters critical to regulatory science and practice. These events, often hosted at the request of FDA leadership, provide space for expert analysis and candid discussion on FDA’s priority issues. See below for upcoming events.

Past Events

Advancing Rare Disease Therapies Through an FDA Rare Disease Innovation Hub

The Reagan-Udall Foundation for the FDA, in collaboration with FDA’s Rare Disease Innovation Hub, hosted a public meeting on October 16, 2024.

Virtual Public Meeting on FDA's Final Rule on Requirements for Additional Traceability Records for Certain Foods

On October 7, we hosted a virtual public meeting to hear insights on the Final Rule on Requirements for Additional Traceability Records from both FDA leadership and other experts from across food industry sectors.

Advancing Treatments for Post-Traumatic Stress Disorder

The Reagan-Udall Foundation for the FDA, in support of FDA’s ongoing focus on PTSD, convened “Advancing Treatments for Post-Traumatic Stress Disorder,” a public meeting with stakeholder comment.

Scientific Advancements in Gene Therapies: Opportunities for Global Regulatory Convergence

The Reagan-Udall Foundation for the FDA, in collaboration with the Bill & Melinda Gates Foundation, will host a hybrid public workshop on "Scientific Advancements in Gene Therapies: Opportunities for Global Regulatory Convergence."
-

Online Controlled Substances Summit

The Food and Drug Administration (FDA) and the Reagan-Udall Foundation for the FDA convened the fifth Online Controlled Substances Summit.

Implementing the RAISE Action Framework

Implementing the RAISE Action Framework Webinar July 16, 2024 | 2-3pm (eastern)  

Understanding Current Use of Ketamine for Emerging Areas of Therapeutic Interest

The Reagan-Udall Foundation for the FDA, in collaboration with the FDA, hosted a hybrid public workshop on "Understanding Current Use of Ketamine for Emerging Areas of Therapeutic Interest."

Real-World Evidence Webinar Series: Considerations Regarding Non-Interventional Studies for Drug and Biological Products

Join the Reagan-Udall Foundation and FDA for a Real-World Evidence Webinar on May 30, 2024, discussing key considerations for non-interventional studies in drug and biologic product development.

Natural History Studies and Registries in the Development of Rare Disease Treatments

The Reagan-Udall Foundation for the FDA, in collaboration with FDA’s Rare Diseases Team within the Office of Rare Diseases, Pediatrics, Urologic and Reproductive Medicine; Office of New Drugs; Center for Drug Evaluation and Research and the National Institutes of Health’s Division of Rare Diseases Research Innovation within the National Center for Advancing Translational Sciences, is hosting a public workshop.

2024 Annual Public Meeting

Each year, the Reagan-Udall Foundation for the FDA conducts an annual public meeting to discuss its activities in support of the FDA.